vTv Therapeutics (NASDAQ:VTVT) Releases Quarterly Earnings Results, Beats Expectations By $0.32 EPS

vTv Therapeutics (NASDAQ:VTVT) released its earnings results on Thursday. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.32, Zacks reports. The company had revenue of $0.02 million during the quarter.

vTv Therapeutics Stock Down 5.5 %

Shares of NASDAQ:VTVT opened at $16.64 on Friday. The firm has a 50-day simple moving average of $16.97 and a 200 day simple moving average of $15.44. The company has a market cap of $53.08 million, a PE ratio of -3.67 and a beta of 1.07. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $29.85.

Wall Street Analysts Forecast Growth

VTVT has been the subject of several research analyst reports. Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They issued a “buy” rating and a $35.00 target price for the company. StockNews.com assumed coverage on shares of vTv Therapeutics in a research report on Wednesday. They set a “sell” rating for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.